IC43重组铜绿假单胞菌疫苗在机械通气重症患者中的疗效、免疫原性与安全性:一项随机临床试验
这项确证性、随机、多中心、安慰剂对照、双盲2/3期研究纳入800例18至80岁、入住ICU且预期需机械通气≥48小时的非外科患者,按1:1随机接受IC43 100 μg或生理盐水安慰剂,间隔7天两次接种。主要疗效终点为首次接种后28天全因死亡率,IC43组为29.2%,安慰剂组为27.7%(P = .67),无显著差异。总体生存率(Kaplan-Meier法,P = .46)及至少一次确诊铜绿假单胞菌侵袭性感染或呼吸道感染的患者比例两组亦无显著差异。IC43组OprF/I抗体滴度几何平均倍数在第一剂后为1.5,第二剂后第28天为20,第180天为2.9。安慰剂组至少一次不良事件发生率96.5%,显著高于IC43组93.1%(P = .04)。作者结论:IC43 100 μg疫苗耐受性良好、免疫原性高,但相比安慰剂在总体死亡率方面未提供临床获益。
要点
- IC43 100 μg疫苗组28天全因死亡率为29.2%,安慰剂组为27.7%,差异无统计学意义(P = .67)。
- 总体生存率(Kaplan-Meier生存估计,P = .46)及至少一次确诊铜绿假单胞菌侵袭性感染或呼吸道感染的比例两组无显著差异。
- OprF/I抗体滴度几何平均倍数:第一剂后1.5,第二剂后第28天20,第180天2.9。
- 至少一次不良事件发生率安慰剂组96.5%显著高于IC43组93.1%(P = .04);IC43组未报告相关严重不良事件。
- 最常见的严重不良事件(IC43组 vs 安慰剂组):呼吸衰竭6.9% vs 5.7%,感染性休克4.1% vs 6.5%,心脏骤停4.3% vs 5.7%,多器官衰竭4.6% vs 5.5%,脓毒症4.6% vs 4.2%。
适用人群与场景
- 年龄18至80岁、入住ICU且预期需要机械通气≥48小时的非外科患者。
处置流程与药物剂量
- IC43 100 μg或生理盐水安慰剂,间隔7天接种两次。
研究设计与关键结果
- 确证性、随机、多中心、安慰剂对照、双盲2/3期研究,纳入800例非外科ICU患者,1:1随机接受IC43 100 μg或生理盐水安慰剂,间隔7天两次接种。
- 主要疗效终点28天全因死亡率:IC43组29.2% vs 安慰剂组27.7%(P = .67)。
- 总体生存率(Kaplan-Meier生存估计,P = .46)及至少一次确诊铜绿假单胞菌侵袭性感染或呼吸道感染的比例两组无显著差异。
- OprF/I抗体滴度几何平均倍数:第一剂后1.5,第二剂后第28天20,第180天2.9。
- 至少一次不良事件发生率:安慰剂组96.5% vs IC43组93.1%(P = .04)。
- 最常见严重不良事件(IC43组 vs 安慰剂组):呼吸衰竭6.9% vs 5.7%,感染性休克4.1% vs 6.5%,心脏骤停4.3% vs 5.7%,多器官衰竭4.6% vs 5.5%,脓毒症4.6% vs 4.2%;IC43组未报告相关严重不良事件。
证据类型、等级与局限
- 证据类型:确证性、随机、多中心、安慰剂对照、双盲2/3期临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:IC43 100 μg疫苗在大型非外科机械通气患者群体中耐受性良好,免疫原性高,但相比安慰剂在总体死亡率方面未提供临床获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pseudomonas aeruginosa infections are a serious threat in intensive care units (ICUs). The aim of this confirmatory, randomized, multicenter, placebo-controlled, double-blind, phase 2/3 study was to assess the efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in non-surgical ICU patients.
METHODS: Eight hundred patients aged 18 to 80 years admitted to the ICU with expected need for mechanical ventilation for ≥ 48 h were randomized 1:1 to either IC43 100 μg or saline placebo, given in two vaccinations 7 days apart. The primary efficacy endpoint was all-cause mortality in patients 28 days after the first vaccination. Immunogenicity and safety were also evaluated.
FINDINGS: All-cause mortality rates at day 28 were 29.2% vs 27.7% in the IC43 and placebo groups, respectively (P = .67). Overall survival (Kaplan-Meier survival estimates, P = .46) and proportion of patients with ≥ one confirmed P. aeruginosa invasive infection or respiratory tract infection also did not differ significantly between both groups. The geometric mean fold increase in OprF/I titers was 1.5 after the first vaccination, 20 at day 28, after the second vaccination, and 2.9 at day 180. Significantly more patients in the placebo group (96.5%) had ≥ one adverse event (AE) versus the IC43 100 μg group (93.1%) (P = .04). The most frequently reported severe AEs in the IC43 and placebo groups were respiratory failure (6.9% vs 5.7%, respectively), septic shock (4.1% vs 6.5%), cardiac arrest (4.3% vs 5.7%), multiorgan failure (4.6% vs 5.5%), and sepsis (4.6% vs 4.2%). No related serious AEs were reported in the IC43 group.
INTERPRETATION: The IC43 100 μg vaccine was well tolerated in this large population of medically ill, mechanically ventilated patients. The vaccine achieved high immunogenicity but provided no clinical benefit over placebo in terms of overall mortality.
TRIAL REGISTRATION: https://clinicaltrials.gov (NCT01563263). Registration was sent to ClinicalTrials.gov on March 14, 2012, but posted by ClinicalTrials.gov on March 26, 2012. The first subject was included in the trial on March 22, 2012.
参考来源
- Adlbrecht C, Wurm R, Depuydt P, et al. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial. Crit Care. 2020. PMID: 32131866. doi:10.1186/s13054-020-2792-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。